Current Report Filing (8-k)
September 07 2017 - 04:32PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(D)
OF THE SECURITIES EXCHANGE ACT OF 1934
September 7, 2017 (September 5, 2017)
Date of Report (Date of earliest event reported)
ELITE
PHARMACEUTICALS, INC.
(Exact name of registrant as specified in
its charter)
Nevada
|
|
001-15697
|
|
22-3542636
|
(State
or other jurisdiction
|
|
(Commission
|
|
(IRS Employer
|
of incorporation)
|
|
File Number)
|
|
Identification No.)
|
165 Ludlow Avenue, Northvale, New Jersey
07647
(Address of principal executive offices)
(201) 750-2646
(Registrant’s telephone number, including
area code)
|
(Former name or former address, if changed since last report.)
|
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
|
¨
|
Written communications pursuant to Rule 425 under the
Securities Act (17 CFR 230.425)
|
|
¨
|
Soliciting material pursuant to Rule 14a-12 under the
Exchange Act (17 CFR 240.14a-12)
|
|
¨
|
Pre-commencement communications pursuant to Rule 14d-2(b)
under the Exchange Act (17 CFR 240.14d-2(b))
|
|
¨
|
Pre-commencement communications pursuant to Rule 13e-4(c)
under the Exchange Act (17 CFR 240.13e-4(c))
|
Indicate by check mark whether the registrant is an emerging
growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2
of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
¨
If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards
provided pursuant to Section 13(a) of the Exchange Act.
¨
Elite Pharmaceuticals, Inc. ("Elite" or the “Company")
received a Complete Response (CR) from the U.S. Food & Drug Administration (FDA) for its Percocet generic ANDA application.
The FDA stated that the response to “the CR letter will be considered to represent a MINOR AMENDMENT, given that the deficiencies
have been classified as MINOR.” Elite intends to submit a “MINOR AMENDMENT” shortly to address the
deficiencies listed. The Percocet generic ANDA submission was received for review by the FDA in November 2016.
Caution Concerning Forward Looking Statements
This Current Report contains “forward-looking statements”
within the meaning of the Private Securities Litigation Reform Act of 1995. Including those related to the effects, if any, on
future results, performance or other expectations that may have some correlation to the subject matter of this Current Report,
readers are cautioned that such forward-looking statements involve risks and uncertainties including, without limitation, Elite’s
ability to obtain FDA approval of the transfers of the ANDAs or the timing of such approval process, delays, uncertainties, inability
to obtain necessary ingredients and other factors not under the control of Elite, which may cause actual results, performance or
achievements of Elite to be materially different from the results, performance or other expectations that may be implied by these
forward-looking statements. These forward-looking statements may include statements regarding the expected timing of approval,
if at all, of SequestOx™ by the FDA, the steps Elite may take as a result of the CRL, the results of an End of Review Meeting
and what actions the FDA may require of Elite in order to obtain approval of the NDA. These forward-looking statements are not
guarantees of future action or performance. These risks and other factors, including, without limitation, Elite’s ability
to obtain sufficient funding under the LPC Agreement or from other sources, the timing or results of pending and future clinical
trials, regulatory reviews and approvals by the Food and Drug Administration and other regulatory authorities, intellectual property
protections and defenses, and the Elite’s ability to operate as a going concern, are discussed in Elite's filings with the
Securities and Exchange Commission, including its reports on forms 10-K, 10-Q and 8-K. Elite is under no obligation to update or
alter its forward-looking statements, whether as a result of new information, future events or otherwise.
SIGNATURE
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Dated: September 7, 2017
|
|
ELITE PHARMACEUTICALS, INC.
|
|
|
|
|
|
|
|
By:
|
/s/ Nasrat Hakim
|
|
|
Nasrat Hakim, President and CEO
|
Elite Pharmaceuticals (QB) (USOTC:ELTP)
Historical Stock Chart
From Feb 2024 to Mar 2024
Elite Pharmaceuticals (QB) (USOTC:ELTP)
Historical Stock Chart
From Mar 2023 to Mar 2024